Sandoz Picks Up Pfizer's Infliximab Biosimilar
This article was originally published in Scrip
Executive Summary
Novartis AG's generics business Sandoz is bulking up its budding biosimilars portfolio by acquiring the rights to Pfizer Inc.'s PF-06438179, a biosimilar version of infliximab (Johnson and Johnson's Remicade), in Europe.
You may also be interested in...
Pfizer's Infliximab Biosimilar Approved In US But Won't Launch Against Inflectra
Ixifi (infliximab-qbtx), which references Janssen's Remicade, marks first US approval of a biosimilar developed entirely by Pfizer; big pharma says it is not currently planning to launch Ixifi because it remains "committed" to marketing Celltrion's Inflectra.
Pfizer's Infliximab Biosimilar Approved In US But Won't Launch Against Inflectra
Ixifi (infliximab-qbtx), which references Janssen's Remicade, marks first US approval of a biosimilar developed entirely by Pfizer; big pharma says it is not currently planning to launch Ixifi because it remains "committed" to marketing Celltrion's Inflectra.
Podcast: Creating A Digital Biotech Story
In this latest instalment of the In Vivo podcast Daniel Lofaso, CEO of Digital Elevator, talks about the common mistakes biotech companies make when trying to build their brand, how to connect with varied audiences and key trends the industry should keep track of in digital marketing.